Abstract
Selective accumulation of an exogenous enzyme or activating agent at a target cell allows use of prodrugs that will be unmasked only at this site. This can reduce the side effects of chemotherapy and allow more potent drugs to be used in various treatments. Examples of this two-step prodrug therapy include antibody- (ADEPT, ADAPT), genetic- (GDEPT, VDEPT) and macromolecule-based approaches (PDEPT, LEAPT). Carbohydrate chemistry and glycobiology feature in each of these areas and is the focus of this review.
Keywords: Abzymes, antibodies, asialoglycoprotein receptor, daunorubicin, doxorubicin, glycoconjugates, glycosidases, HPMA, prodrugs
Current Drug Delivery
Title: Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective
Volume: 4 Issue: 4
Author(s): Todd A. Houston
Affiliation:
Keywords: Abzymes, antibodies, asialoglycoprotein receptor, daunorubicin, doxorubicin, glycoconjugates, glycosidases, HPMA, prodrugs
Abstract: Selective accumulation of an exogenous enzyme or activating agent at a target cell allows use of prodrugs that will be unmasked only at this site. This can reduce the side effects of chemotherapy and allow more potent drugs to be used in various treatments. Examples of this two-step prodrug therapy include antibody- (ADEPT, ADAPT), genetic- (GDEPT, VDEPT) and macromolecule-based approaches (PDEPT, LEAPT). Carbohydrate chemistry and glycobiology feature in each of these areas and is the focus of this review.
Export Options
About this article
Cite this article as:
Houston A. Todd, Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective, Current Drug Delivery 2007; 4 (4) . https://dx.doi.org/10.2174/156720107782151278
DOI https://dx.doi.org/10.2174/156720107782151278 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors
Current Topics in Medicinal Chemistry S-Phase Kinase-Associated Protein-2 and Nuclear Factor-kappa Beta as Molecular Targets of Oral Burkitt’s Lymphoma Cell Induced by Quinolinone Derivate-Vesnarinone
Current Signal Transduction Therapy Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy Synthesis of New Thiazolyl-Pyrazoline Derivatives and Evaluation of Their Antimicrobial, Cytotoxic and Genotoxic Effects
Letters in Drug Design & Discovery Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Drug-Membrane Interactions: Significance for Medicinal Chemistry
Current Medicinal Chemistry The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Self-Adjuvanting Lipopeptide Vaccines
Current Medicinal Chemistry Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry